This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Myovant Sciences 과거 순이익 실적

과거 기준 점검 0/6

핵심 정보

-0.80%

순이익 성장률

8.49%

주당순이익(EPS) 성장률

Biotechs 산업 성장률	17.04%
매출 성장률	79.81%
자기자본이익률	n/a
순이익률	-48.47%
최근 순이익 업데이트	31 Dec 2022

최근 과거 실적 업데이트

Recent updates

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M

Jan 26

Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication

Aug 09

Myovant stock gains ~6% after hours on Q1 revenue jump

Jul 27

Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree

Jul 18

Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Apr 28

Myovant: Poised To Overcome Regulatory Issues

Apr 26

Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels

Apr 13

Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play

Mar 26

Myovant: Catalysts Powering More Upside

Jan 02

Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

May 14

New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Feb 17

Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Feb 13

Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Jan 12

Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?

Dec 23

Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain

Nov 18

매출 및 비용 세부 내역

Myovant Sciences가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NYSE:MYOV 매출, 비용 및 순이익 (USD Millions)
날짜	매출	순이익	일반관리비	연구개발비
31 Dec 22	379	-184	317	-1
30 Sep 22	333	-190	303	0
30 Jun 22	306	-166	277	0
31 Mar 22	231	-206	259	0
31 Dec 21	198	-228	244	72
30 Sep 21	145	-238	222	0
30 Jun 21	67	-284	194	0
31 Mar 21	59	-255	156	0
31 Dec 20	35	-239	126	11
30 Sep 20	33	-250	96	-102
30 Jun 20	33	-254	81	-51
31 Mar 20	0	-289	82	0
31 Dec 19	0	-299	62	59
30 Sep 19	0	-284	54	219
30 Jun 19	0	-279	48	222
31 Mar 19	0	-274	42	0
31 Dec 18	0	-247	37	204
30 Sep 18	0	-218	33	180
30 Jun 18	0	-182	29	150
31 Mar 18	0	-143	24	117
31 Dec 17	0	-117	21	96
30 Sep 17	0	-83	17	67
30 Jun 17	0	-88	14	47
31 Mar 17	0	-83	12	44

양질의 수익: MYOV 은(는) 현재 수익성이 없습니다.

이익 마진 증가: MYOV는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: MYOV은 수익성이 없으며 지난 5년 동안 손실이 연평균 0.8% 증가했습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 MYOV의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: MYOV은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(52.4%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: MYOV의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2023/03/12 13:55
종가	2023/03/09 00:00
수익	2022/12/31
연간 수익	2022/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Myovant Sciences Ltd.는 8명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Brian Skorney	Baird
Mohit Bansal	Citigroup Inc
Jason Butler	Citizens JMP Securities, LLC

This company has been acquired

Myovant Sciences 과거 순이익 실적

과거 기준 점검 0/6

핵심 정보

최근 과거 실적 업데이트

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

Not The Buyout Offer That Myovant Shareholders Hoped For

Myovant Sciences Ltd. Appoints Shigeyuki Nishinaka as Director

Myovant May Delist from the New York Stock Exchange

Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer

Principal Financial Officer recently sold US$174k worth of stock

Women Can Thank Pfizer And Myovant For MYFEMBREE

Myovant Sciences: Regulatory Overhang Cleared

General Counsel & Corporate Secretary recently sold US$569k worth of stock

Price target increased to US$20.40

Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication

Myovant Sciences and Pfizer Inc. Receive U.S. FDA Approval of MYFEMBREE®, A Once-Daily Treatment for the Management of Moderate to Severe Pain Associated with Endometriosis

Myovant Sciences Ltd., Annual General Meeting, Oct 21, 2022

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Myovant stock gains ~6% after hours on Q1 revenue jump

CEO & Director recently sold US$144k worth of stock

Consensus EPS estimates fall by 29%

Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree

Myovant Sciences and Pfizer Inc. Announce Results of the Phase 3 Spirit 1 and Spirit 2 Studies of Investigational Once-Daily Relugolix Combination Therapy

Myovant Sciences and Pfizer Inc. Announce FDA Acceptance of Supplemental New Drug Application for Myfembree

Consensus EPS estimates fall by 31%

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Myovant Sciences Ltd. Announces European Commission Approval for Orgovyx (Relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer

Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Price target decreased to US$22.80

Less than half of directors are independent

Myovant: Poised To Overcome Regulatory Issues

General Counsel & Corporate Secretary recently sold US$84k worth of stock

Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels

Price target decreased to US$24.80

Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play

Myovant Sciences Receives Positive CHMP Opinion for Orgovyx® (Relugolix) for the Treatment of Advanced Prostate Cancer

Forecast to breakeven in 2024

CEO & Director recently sold US$292k worth of stock

Myovant Sciences Ltd. Provides Revenue Guidance for the Three Months Ended December 31, 2021

General Counsel & Corporate Secretary recently sold US$73k worth of stock

Myovant: Catalysts Powering More Upside

Chief Medical Officer exercised options and sold US$62k worth of stock

Price target decreased to US$28.40

General Counsel & Corporate Secretary recently sold US$144k worth of stock

Chief Medical Officer exercised options and sold US$116k worth of stock

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis

Price target decreased to US$33.25

Chief Medical Officer exercised options and sold US$342k worth of stock

Less than half of directors are independent

Key Executive recently sold US$70k worth of stock

Myovant Sciences and Pfizer Inc. Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids

The U.S. Food and Drug Administration Informs Myovant Sciences Ltd. by Teleconference That They Have Placed A Partial Clinical Hold on the Phase 3 Serene Study (MVT-601-050)

Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

Consensus forecasts updated

General Counsel & Corporate Secretary recently sold US$202k worth of stock

General Counsel & Corporate Secretary notifies of intention to sell stock

Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 Liberty Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

Analysts update estimates

New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Revenue and earnings miss expectations

Myovant Sciences and Pfizer Inc Announces Positive Data from Phase 3 SPIRIT Extension Study of Relugolix Combination Therapy in Women with Endometriosis

Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Analysts increase revenue estimates to US$42.9m

Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer

Myovant Sciences Ltd Appoints David Marek as Principal Executive Officer and Member of the Board of Directors

Key Executive notifies of intention to sell stock

Myovant Sciences Ltd. and Pfizer Inc. Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’S Health

New 90-day high: US$27.41

Price target raised to US$33.14

General Counsel & Corporate Secretary exercised options and sold US$176k worth of stock

Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?